Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707298 | 0.84 | KMT2A (0.55) | TP53MALT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2682720 | 0.80 | ALDH1A1 (0.47) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2707418 | 0.80 | KDM4E (0.45) | TP53MALT1NPC1RAB9ACETP | |
| SCHEMBL2709571 | 0.79 | HTT (0.51) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2708169 | 0.78 | BCHE (0.56) | NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL2709340 | 0.78 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL20564258 | 0.78 | ALDH1A1 (0.59) | RAB9ASMN1; SMN2ALDH1A1KDM4ELMNA | |
| SCHEMBL13100945 | 0.78 | PTPN1 (0.60) | TP53MDM4RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL202175 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL671016 | 0.76 | ALDH1A1 (0.54) | NPC1RAB9ACETPSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1789042-A4 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1789042-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | IL2, IL4, IRF3 | TP53 154/4885MDM4 242/4885MALT1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.